Patent 9056919 was granted and assigned to Nuclea Biotechnologies on June, 2015 by the United States Patent and Trademark Office.
The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment.